S0902, Phase II Study of Bendamustine Plus Rituximab for the Treatment of Refractory B-Cell Chronic Lymphocytic Leukemia
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bendamustine (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 06 Mar 2015 Biomarkers information updated
- 21 Jul 2009 New trial record